79 related articles for article (PubMed ID: 31804159)
1. Gene Expression Assay in the Management of Early Breast Cancer.
Caputo R; Cianniello D; Giordano A; Piezzo M; Riemma M; Trovò M; Berretta M; De Laurentiis M
Curr Med Chem; 2020; 27(17):2826-2839. PubMed ID: 31804159
[TBL] [Abstract][Full Text] [Related]
2. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
[TBL] [Abstract][Full Text] [Related]
4. Multigene tests for breast cancer: the physician's perspective.
Cognetti F; Biganzoli L; De Placido S; Del Mastro L; Masetti R; Naso G; Pruneri G; Santini D; Tondini CA; Tinterri C; Tonini G; Barni S
Oncotarget; 2021 Apr; 12(9):936-947. PubMed ID: 33953847
[TBL] [Abstract][Full Text] [Related]
5. Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer.
Bottosso M; Miglietta F; Vernaci GM; Giarratano T; Dieci MV; Guarneri V; Griguolo G
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38656833
[TBL] [Abstract][Full Text] [Related]
6. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):66-73. PubMed ID: 19125125
[TBL] [Abstract][Full Text] [Related]
7. Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management.
Irelli A; Sirufo MM; Quaglione GR; De Pietro F; Bassino EM; D'Ugo C; Ginaldi L; De Martinis M
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672165
[TBL] [Abstract][Full Text] [Related]
8. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).
Ohnstad HO; Blix ES; Akslen LA; Gilje B; Raj SX; Skjerven H; Borgen E; Janssen EAM; Mortensen E; Brekke MB; Falk RS; Schlichting E; Boge B; Songe-Møller S; Olsson P; Heie A; Mannsåker B; Vestlid MA; Kursetgjerde T; Gravdehaug B; Suhrke P; Sanchez E; Bublevic J; Røe OD; Geitvik GA; Halset EH; Rypdal MC; Langerød A; Lømo J; Garred Ø; Porojnicu A; Engebraaten O; Geisler J; Lyngra M; Hansen MH; Søiland H; Nakken T; Asphaug L; Kristensen V; Sørlie T; Nygård JF; Kiserud CE; Reinertsen KV; Russnes HG; Naume B
ESMO Open; 2024 Jun; 9(6):103475. PubMed ID: 38838499
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer gene expression signatures: development and clinical significance-a narrative review.
Li S; Yu X; Xu Y
Transl Breast Cancer Res; 2023; 4():7. PubMed ID: 38751471
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option?
Schunkert EM; Zhao W; Zänker K
Biomed Hub; 2018; 3(3):1-17. PubMed ID: 31988964
[TBL] [Abstract][Full Text] [Related]
11. Genomic Signatures in Luminal Breast Cancer.
Puppe J; Seifert T; Eichler C; Pilch H; Mallmann P; Malter W
Breast Care (Basel); 2020 Aug; 15(4):355-365. PubMed ID: 32982645
[TBL] [Abstract][Full Text] [Related]
12. The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer.
Ahmed S; Pati S; Le D; Haider K; Iqbal N
J Surg Oncol; 2020 Aug; 122(2):144-154. PubMed ID: 32346902
[TBL] [Abstract][Full Text] [Related]
13. The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review.
Gordon-Craig S; Parks RM; Cheung KL
Oncol Ther; 2020 Dec; 8(2):231-250. PubMed ID: 32700048
[TBL] [Abstract][Full Text] [Related]
14. Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.
Mazo C; Barron S; Mooney C; Gallagher WM
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32369904
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of genomic signatures in young breast cancer patients: a systematic review.
Villarreal-Garza C; Ferrigno AS; De la Garza-Ramos C; Barragan-Carrillo R; Lambertini M; Azim HA
NPJ Breast Cancer; 2020; 6():46. PubMed ID: 33062888
[TBL] [Abstract][Full Text] [Related]
16. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.
Kashyap D; Kaur H
Life Sci; 2020 Apr; 246():117417. PubMed ID: 32044304
[TBL] [Abstract][Full Text] [Related]
17. Molecular Drivers of Onco
Buus R; Sestak I; Kronenwett R; Ferree S; Schnabel CA; Baehner FL; Mallon EA; Cuzick J; Dowsett M
J Clin Oncol; 2021 Jan; 39(2):126-135. PubMed ID: 33108242
[TBL] [Abstract][Full Text] [Related]
18. Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Bou Zerdan M; Ibrahim M; Nakib CE; Hajjar R; Assi HI
Front Oncol; 2020; 10():609100. PubMed ID: 33665165
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted adjuvant therapy of luminal early breast cancer in 2020.
Harbeck N
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):53-58. PubMed ID: 33337614
[TBL] [Abstract][Full Text] [Related]
20. Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosis.
Baskota SU; Dabbs DJ; Clark BZ; Bhargava R
Mod Pathol; 2021 Jan; 34(1):70-76. PubMed ID: 32740650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
